3.1 Glaucoma Studies examining the effect of GLP-1RAs on glaucoma risk in diabetes patients is a research hotspot that emerged in recent years
But they can now narrow their focus to the GLP-1 drug segment specifically with funds that have come to market tapping directly into the weight loss thematic opportunity
Current EU labeling limits use to patients after 3 prior lines, but permits 1.5 mg/kg every-two-week maintenance after 6 months of CR or better
Any changes in sexual function are likely related to weight loss, hormonal normalization, improved body image, and enhanced metabolic health rather than a direct medication effect
Based on the available data, tirzepatide has the lowest discontinuation rates and similar or slightly lower GI side effect rates compared to semaglutide
Sodium, potassium, calcium, magnesium, and chloride are some of the most common electrolytes